Cat. No. 5838
Biological ActivityGIP receptor antagonist (IC50 = 2.6μM). Inhibits GIP-stimulated insulin release from pancreatic β cells in vitro. In ob/ob mice, blocks the effects of GIP on insulin release and plasma glucose levels. Also improves intraperitoneal glucose tolerance, insulin sensitivity, and glucose response to feeding in ob/ob mice.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Irwin et al (2007) Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 50 1532. PMID: 17486314.
Gault et al (2002) Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem.Biophys.Res.Commun. 290 1420. PMID: 11820780.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses [Pro3]-GIP (Mouse) from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: [Pro3]-GIP (Mouse), supplier, GIP, receptors, antagonists, antagonism, glucose-dependent, insulinotropic, polypeptide, diabetes, obesity, glucose, insulin, Tocris Bioscience, GIP Receptor Antagonist products
Find multiple products by catalog number
April 1 - 5, 2017
Washington, D.C., USA